# OnCo record depatuxizumab-mafodotin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/depatuxizumab-mafodotin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "depatuxizumab-mafodotin" ;
  schema:name "Depatuxizumab mafodotin"@en ;
  schema:alternateName "ABT-414"@en, "Depatux-M"@en ;
  schema:description "Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019."@en ;
  schema:url <https://onco.cc/drugs/depatuxizumab-mafodotin/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin> ;
  schema:citation <https://en.wikipedia.org/wiki/Depatuxizumab_mafodotin> ;
  onco:status "negative" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "EGFR-targeted antibody-drug conjugate (MMAF payload)" ;
  onco:related <https://onco.cc/drugs/temozolomide/> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/tubulin/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .